Journals / Medicine Science / 2020 / Cilt: 9 - Sayı: 4

Clinical correlation and determination of Dkk-1 and sclerostin levels in patients with rheumatoid arthritis

Pages
1053–1060
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The sample of our study can be enlarged and further studies are required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study is to compare serum Sclerostin and Dickkopf-1 (Dkk-1) levels in patients with rheumatoid artrithis (RA) and healty controls to determine their clinical significance in patients with RA.
📊
Key Findings & Data:To evaluate disease activity score 28 (DAS28) was calculated.
💡
Conclusion & Impact:The sample of our study can be enlarged and further studies are required.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The aim of this study is to compare serum Sclerostin and Dickkopf-1 (Dkk-1) levels in patients with rheumatoid artrithis (RA) and healty controls to determine their clinical significance in patients with RA. Sixty with RA according to American Collage of Rhematology criteria and at least one year follow up, enrolled in this study and compared thırty healty controls. To evaluate disease activity score 28 (DAS28) was calculated. Physical function capasity (disability) was asssessed with Health Assesment Quastionnarie (HAQ) and Nottingham Health Profile (NHP). Erythrocyte Sedimentation Rate, C Reactive Protein, Rheumatoid Factor and anticyclic citrullinated peptide levels were determined by routine laboratory methods. Serum sclerostin and Dkk-1 levels of the patients with RA and healty controls were measured by ELISA. Radiographic assesment of hands joints was evaluated according to the modified Larsen score. Between patients with RA and healty controls, there was significant difference with respect to the age (respectively p=0.00) and significant difference with respect to gender (p=0.033). Serum sclerostin and dickkopf-1 levels were significantly higher (p=0.002, p=0.049) in patients with RA compared to healty controls. Serum sclerostin and dickkopf-1 levels were doesnt correlated with clinical and laboratory parameters of disease activity. There was no significant correlation between radiological scoring of joint damage and serum sclerostin and dickkopf-1levels (p 0.05). This study shows that Serum sclerostin and dickkopf-1 levels were increased in RA patients in comparison to control group but there was no significant correlation with the disease activity and joint damage. The sample of our study can be enlarged and further studies are required.

🔖

Cite This Article

AYDEMİR, Z. S., AKGÖL, G., GÜLKESEN, A., KAYA, A., KAMAN, D., ULUSOY, H. (2020). Clinical correlation and determination of Dkk-1 and sclerostin levels in patients with rheumatoid arthritis. Medicine Science, Cilt: 9 - Sayı: 4, 1053–1060. https://ajindex.com/articles/276843

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Dellhag B, Hosseini N, Bremell T, et al. Disturbed grip function in women with rheumatoid arthritis. J Rheumatol. 2001;28:2624-33
  2. Goronzy JJ, Weyand MC. Rheumatoid arthritis: Epidemiology, pathology and pathogenesis. Klippel JH (editor). Primer on the rheumatic diseases. Atlanta: Arthritis Foundation. 1997:155-61
  3. Ergin S. Romatoid artrit ve Sjögren sendromu. Beyazova M, Gökçe-Kutsal Y (editörler). Fiziksel Tıp ve Rehabilitasyon. Ankara: Öncü Basımevi, 2000;1549-76
  4. Fox DA. Etiology and pathogenesis of rheumatoid arthritis. Kopman WJ (editor). Arthritis and Allied Conditions. Philadelphia: Lippincott Williams and Wilkins. 2001:617-623 5. Deal C. Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep. 2012;14:231-7
  5. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos In. 2011;22:421-33
  6. Sen M. Wnt signalling in rheumatoid arthritis. Rheumatology. 2005;44:708- 13
  7. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007;19:376-82
  8. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid artrhritis. Arthritis Rheum. 1994;37:470-5
  9. Fries JF, Spitz P, Kraines RG, et al. Measurement of patients outcome in arthritis. Arthritis Rheum. 1980;23:137-45
  10. Andresen EM, Meyers AR. Health-related quality of life outcomes measures. Arch Phys Med Rehabil. 2000;81:30-45
  11. Gökçe-Kutsal Y, Osteoporoz tanısında görüntüleme yöntemleri ve histomorfometri, Ed: Gökçe-Kutsal Y, Osteoporoz, 2. Baskı, Ankara. Güneş Kitabevi. 2005:103-124
  12. Bağış S, Camdeviren H, Şahin G, ve ark. Osteoporoz risksorgulama formunun dexa ölçümü yapılacak hastaları ayırd etmede kullanımı. Osteoporoz Dünyasından. 2003;9:96-9
  13. Öncel S. Diğer periferik eklem osteoartritleri. Sarıdoğan M,ed. Tanıdan tedaviye osteoartrit. İstanbul: Nobel Tıp Kitabevi. 2007:163-73
  14. Larsen A. How to apply larsen score in evaluating radiographs of rheumatoid arthritis in long term studies. J Rheumatol 1995;22:1974-5
  15. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036-8
  16. Van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35:26-34
  17. Laan RF, Riel PL, Putte L. Bone mass in patients